Logo image of SRZN

SURROZEN INC (SRZN) Stock Fundamental Analysis

NASDAQ:SRZN - Nasdaq - US86889P2083 - Common Stock - Currency: USD

10.705  -0.44 (-3.9%)

Fundamental Rating

2

Taking everything into account, SRZN scores 2 out of 10 in our fundamental rating. SRZN was compared to 549 industry peers in the Biotechnology industry. SRZN has a great financial health rating, but its profitability evaluates not so good. SRZN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SRZN had negative earnings in the past year.
SRZN had a negative operating cash flow in the past year.
In the past 5 years SRZN always reported negative net income.
SRZN had a negative operating cash flow in each of the past 5 years.
SRZN Yearly Net Income VS EBIT VS OCF VS FCFSRZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -71.15%, SRZN is not doing good in the industry: 62.66% of the companies in the same industry are doing better.
SRZN has a worse Return On Equity (-1439.97%) than 82.70% of its industry peers.
Industry RankSector Rank
ROA -71.15%
ROE -1439.97%
ROIC N/A
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRZN Yearly ROA, ROE, ROICSRZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

SRZN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRZN Yearly Profit, Operating, Gross MarginsSRZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

7

2. Health

2.1 Basic Checks

SRZN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRZN has more shares outstanding
SRZN has less shares outstanding than it did 5 years ago.
SRZN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRZN Yearly Shares OutstandingSRZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SRZN Yearly Total Debt VS Total AssetsSRZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -2.93, we must say that SRZN is in the distress zone and has some risk of bankruptcy.
SRZN has a Altman-Z score (-2.93) which is comparable to the rest of the industry.
SRZN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.93
ROIC/WACCN/A
WACC9.62%
SRZN Yearly LT Debt VS Equity VS FCFSRZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

SRZN has a Current Ratio of 10.02. This indicates that SRZN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.02, SRZN belongs to the best of the industry, outperforming 80.33% of the companies in the same industry.
A Quick Ratio of 10.02 indicates that SRZN has no problem at all paying its short term obligations.
SRZN has a better Quick ratio (10.02) than 80.33% of its industry peers.
Industry RankSector Rank
Current Ratio 10.02
Quick Ratio 10.02
SRZN Yearly Current Assets VS Current LiabilitesSRZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.69% over the past year.
EPS 1Y (TTM)5.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%265.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SRZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.66% on average per year.
SRZN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y59.05%
EPS Next 2Y29.91%
EPS Next 3Y18.68%
EPS Next 5Y8.66%
Revenue Next Year-90%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

SRZN Yearly Revenue VS EstimatesSRZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2030 2031 2032 10M 20M 30M 40M
SRZN Yearly EPS VS EstimatesSRZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SRZN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SRZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRZN Price Earnings VS Forward Price EarningsSRZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRZN Per share dataSRZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

SRZN's earnings are expected to grow with 18.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.91%
EPS Next 3Y18.68%

More info and screens

0

5. Dividend

5.1 Amount

SRZN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURROZEN INC

NASDAQ:SRZN (8/18/2025, 10:31:56 AM)

10.705

-0.44 (-3.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)N/A N/A
Inst Owners64.55%
Inst Owner Change9.37%
Ins Owners0.52%
Ins Owner Change0.21%
Market Cap91.63M
Analysts85
Price Target37.74 (252.55%)
Short Float %0.95%
Short Ratio5.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-436.94%
Min EPS beat(2)-565.79%
Max EPS beat(2)-308.08%
EPS beat(4)2
Avg EPS beat(4)-186.37%
Min EPS beat(4)-565.79%
Max EPS beat(4)82.5%
EPS beat(8)4
Avg EPS beat(8)-96.82%
EPS beat(12)7
Avg EPS beat(12)-56.8%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-48.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.87
P/FCF N/A
P/OCF N/A
P/B 16.15
P/tB 16.15
EV/EBITDA N/A
EPS(TTM)-14.42
EYN/A
EPS(NY)-4.78
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS1.36
BVpS0.66
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.15%
ROE -1439.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.42%
Cap/Sales 0.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.02
Quick Ratio 10.02
Altman-Z -2.93
F-Score6
WACC9.62%
ROIC/WACCN/A
Cap/Depr(3y)19.96%
Cap/Depr(5y)33.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%265.58%
EPS Next Y59.05%
EPS Next 2Y29.91%
EPS Next 3Y18.68%
EPS Next 5Y8.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-90%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y33.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-73.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.54%
OCF growth 3YN/A
OCF growth 5YN/A